Engineering programmable biological therapeutics with unprecedented precision and control over disease-driving mechanisms to eliminate disease at its source
About
About ImmunoBiochem and Pipeline
ImmunoBiochem is developing novel degrader-antibody conjugate (DAC) therapeutics that unlock novel mechanisms of action and enable unprecedented precision in immunology and inflammation. Leveraging modern computational tools and biological models, ImmunoBiochem is redefining antibody conjugates by combining the robustness of ADCs with the catalytic power of targeted protein degraders, unlocking new opportunities to modulate disease pathways not accessible to other modalities.
Antibody Video
Science
Science & Technology Platform
ImmunoBiochem utilizes modern computational tools and robust disease models to develop novel degrader-antibody conjugate (DAC) therapeutics for precision immunology. DACs access unique mechanisms via targets on both the surface and inside disease-driving cells, not accessible to other modalities, with a multi-modal layered logic-gated control of selectivity and potency for precise regulation of immunobiology. ImmunoBiochem’s synthetic payloads, designed with controlled targeted protein degradation catalytic activity, enable unparalleled in vivo programming of biology. Accelerated by modern computational tools and AI, tunable heterofunctional chemistry enables precise engineering of novel non-cytotoxic DAC payloads with favourable biophysical, pharmacological and biological properties, overcoming all of the limitations of ADC payloads like CMC challenges and narrow therapeutic index and unlocking more favorable routes of administration, like subcutaneous delivery.
ImmunoBiochem’s novel DACs are designed to drive unprecedented efficacy, while avoiding the significant side-effects of other modalities. IMB216P, lead molecule for autoimmune disorders, is a CD127/IL7RA-targeted DAC with a JAK1/TYK2 dual-degrader payload that carries out immune system reset and rebalancing at the level of disease-driving T cells, and without lymphodepletion or broad immunosuppression. IMB216P has potential across all major autoimmune indications, including, in IBD, PsO, PsA, SLE, LN, T1D, RA, JIA, SpA, IPF, SjD, GvHD and MS.
